Journal
INTERNATIONAL JOURNAL OF CANCER
Volume 140, Issue 7, Pages 1597-1608Publisher
WILEY
DOI: 10.1002/ijc.30575
Keywords
Burkitt lymphoma; VAR2CSA; cancer; malaria; Plasmodium falciparum; chondroitin sulfate A; CSA; chondroitin sulfate proteoglycan
Categories
Funding
- Harboe Foundation
- European Research Councils under the MalOnco program
- Danish Innovation Foundation
- EUREKA program
- Danish Cancer Society
- Intramural Research Program of the Division of Cancer Epidemiology and Genetics
- National Cancer Institute
- National Institute of Allergy and Infectious Diseases
- National Institutes of Health
- Department of Health and Human Services [N01-CO-12400, AI-001040]
- Lundbeck Foundation [R209-2015-3750] Funding Source: researchfish
- Novo Nordisk Fonden [NNF12OC0002118] Funding Source: researchfish
- The Danish Cancer Society [R146-A9111] Funding Source: researchfish
Ask authors/readers for more resources
Burkitt lymphoma (BL) is a malignant disease, which is frequently found in areas with holoendemic Plasmodium falciparum malaria. We have previously found that the VAR2CSA protein is present on malaria-infected erythrocytes and facilitates a highly specific binding to the placenta. ofCS is absent in other non-malignant tissues and thus VAR2CSA generally facilitates parasite sequestration and accumulation in pregnant women. In this study, we show that the specific receptor for VAR2CSA, the oncofetal chondroitin sulfate ( ofCS), is likewise present in BL tissue and cell lines. We therefore explored whether ofCS in BL could act as anchor site for VAR2CSA-expressing infected erythrocytes. In contrast to the placenta, we found no evidence of in vivo sequestering of infected erythrocytes in the BL tissue. Furthermore, we found VAR2CSA-specific antibody titers in children with endemic BL to be lower than in control children from the same malaria endemic region. The abundant presence of ofCS in BL tissue and the absence of ofCS in non-malignant tissue encouraged us to examine whether recombinant VAR2CSA could be used to target BL. We confirmed the binding of VAR2CSA to BL-derived cells and showed that a VAR2CSA drug conjugate efficiently killed the BL-derived cell lines in vitro. These results identify ofCS as a novel therapeutic BL target and highlight how VAR2CSA could be used as a tool for the discovery of novel approaches for directing BL therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available